Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1485109
This article is part of the Research Topic Immunological Precision Therapeutics: Integrating Multi-Omics Technologies and Comprehensive Approaches for Personalized Immune Intervention View all 25 articles

A New Perspective on Macrophage-targeted Drug Research: The Potential of KDELR2 in Bladder Cancer Immunotherapy

Provisionally accepted
Zhiyi Zhao Zhiyi Zhao 1*Hongling Jia Hongling Jia 2Zhou Sun Zhou Sun 3*Yumeng Li Yumeng Li 2*Lingyun Liu Lingyun Liu 1*
  • 1 First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China
  • 2 Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China
  • 3 China-Japan Union Hospital, Jilin University, Changchun, Jilin Province, China

The final, formatted version of the article will be published soon.

    Bladder cancer is one of the most common malignant tumors affecting the urinary system, and its treatment is still mainly a combination of conventional surgery and radiotherapy and chemotherapy. This means that the patient benefit rate is always limited. It is imperative to explore new potential immunotherapy and targeted therapy drug targets, which will greatly expand the range of diagnosis and treatment options for bladder cancer patients and improve patients' survival space. This study carefully

    Keywords: Bladder cancer, S100A8, TCS, KDELR2, macrophage

    Received: 23 Aug 2024; Accepted: 04 Nov 2024.

    Copyright: © 2024 Zhao, Jia, Sun, Li and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zhiyi Zhao, First Affiliated Hospital of Jilin University, Changchun, 130012, Jilin Province, China
    Zhou Sun, China-Japan Union Hospital, Jilin University, Changchun, 130033, Jilin Province, China
    Yumeng Li, Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong Province, China
    Lingyun Liu, First Affiliated Hospital of Jilin University, Changchun, 130012, Jilin Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.